Patterns of asthma medication use and hospital discharges in New Zealand

• Published in: The journal of allergy and clinical immunology. Global 2024-08, Vol.3 (3), p.100258-100258, Article 100258
• Main Authors: Noble, Jonathan, Hatter, Lee, Eathorne, Allie, Hills, Thomas, Bean, Orlagh, Bruce, Pepa, Weatherall, Mark, Beasley, Richard
• Format: Article
• Language: English
• Subjects: Asthma; Brief Report; dispensing; guidelines; hospital admission; ICS/formoterol; New Zealand
• ISSN: 2772-8293; 2772-8293
• DOI: 10.1016/j.jacig.2024.100258

In New Zealand a progressive increase in budesonide/formoterol dispensing, accompanied by a reduction in dispensing of short-acting β2-agonists (SABAs), inhaled corticosteroids (ICSs), and other ICS/long-acting β2-agonists (ICSs/LABAs), occurred in the 18-month period following publication of the 2020 New Zealand asthma guidelines, which recommended budesonide/formoterol anti-inflammatory reliever therapy. Our aim was to investigate more recent trends in asthma medication use and asthma hospital discharges in New Zealand. New Zealand national dispensing data for inhalers for the period from January 2010 to December 2022 were reviewed for patients aged 12 years and older. Monthly rates of dispensing of budesonide/formoterol, ICSs, other ICS/LABAs, and SABAs were displayed graphically by locally weighted scatterplot smoother plots. The rates of dispensing and hospital discharge for asthma were compared between the past 6 months for which dispensing data were available (July-December 2022) and the corresponding period from July to December 2019. There has been a progressive increase in dispensing of budesonide/formoterol since 2019, with a 108% increase between the period from July to December 2019 and the period from July to December 2022 in adolescents and adults. In contrast, there was a reduction in rates of dispensing of other ICS/LABAs, ICSs, and SABAs by 3%, 18%, and 5%, respectively. During this period, there was a 17% reduction in hospital discharges for asthma. There has been a further widespread uptake of ICS/formoterol reliever and/or maintenance therapy in adolescents and adults with asthma in New Zealand. The changes in prescribing practice have been temporally associated with a reduction in hospital admissions for asthma.